AFP and hepatocellular carcinoma: The patients with non-SVR undergoing DAA therapy, compared to those with SVR, had a higher ratio of Child–Pugh stage B (33.3% vs. 17.0%, p = 0.361), ALBI grade 2/3 (77.8% vs. 56.8%, p = 0.316), HCC size (mean 6.09 cm vs. 3.96 cm, p = 0.087), beyond up-to-7 criteria (55.6% vs. 36.4%, p = 0.295), HCC with PD (44.5% vs. 12.5%, p = 0.198), and AFP over 400 ng/mL (33.3% vs. 13.7%, p = 0.142), but these differences were all non-significant.